Navigation Links
Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
Date:8/9/2012

BLUE BELL, Pa., Aug. 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2012.

Total revenue was $436,000 and $2.1 million for the three and six months ended June 30, 2012, compared to $2.4 million and $5.5 million for the same periods in 2011.

Total operating expenses were $7.2 million and $13.1 million for the three and six months ended June 30, 2012, compared to $7.6 million and $15.0 million for the same periods in 2011.

The net loss attributable to common stockholders for the three and six months ended June 30, 2012, was $4.1 million, or $0.03 per share, and $12.4 million, or $0.09 per share, as compared with a net loss attributable to common stockholders of $2.8 million, or $0.02 per share, and $5.2 million, or $0.04 per share, for the three and six months ended June 30, 2011.

Revenue The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company's contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $234,000 and $1.7 million for the three and six months ended June 30, 2012, versus $1.7 million and $4.5 million for the same periods in 2011. This NIAID contract, which exceeds $23 million over five years (plus two additional option years), is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for the three and six months ended June 30, 2012, were $4.5 million and $8.6 million for the three and six months ended June 30, 2012 as compared to $4.5 million and $8.9 million for the same periods in 2011. General and administrative expenses for the three and six months ended June 30, 2012 were $2.7 million and $5.2 million versus $3.1 million and $6.4 million for the same periods in 2011.

Net Loss Attributable to Common St
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
2. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
3. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
4. Inovio Pharmaceuticals to Present at JMP Investor Conference
5. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
6. Inovio Pharmaceuticals to Present at SPI 2012
7. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
10. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
11. Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Conn., Sept. 21 In a platform presentation at ... the Study of Diabetes (EASD) in Stockholm, investigators for ... the results of a clinical study evaluating a new ... (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues ...
... Inc. (Nasdaq: VVUS ) today announced positive ... Controlled Release Capsules, an investigational therapy for treatment of ... Americans. The findings come from the ... subset of patients who completed the previously reported 56-week ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... TORONTO, April 24, 2014 Pregnant immigrants from ... require increased monitoring during pregnancy, according to new ... published today in the British Journal of ... preeclampsia and eclampsia rates among immigrants and native-born ... Canada (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) ...
(Date:4/23/2014)... American Society for Radiation Oncology (ASTRO) has issued ... Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," ... in the treatment of endometrial cancer. The guideline,s ... issue of Practical Radiation Oncology (PRO), ... full-length guideline is available as an open-access article ...
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... the potential health benefits of probiotics, antioxidants and other ... And the chemical industry is getting in on the ... deter growth, so the industry is responding with clinical ... cover story in Chemical & Engineering News ... Society. , Melody M. Bomgardner, a senior editor at ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... , WASHINGTON , Jan. 29 In today,s ... Bipartisan Policy Center,s (BPC) plan for reforming health care, entitled: ... as a bipartisan health care proposal that is worthy of ... plan, which was developed by former U.S. Senate Majority Leaders ...
... more likely to strike whites than blacks, researchers find , ... its kind finds that Parkinson,s disease in the United States ... whites and Hispanics are twice as likely to develop the ... an analysis of data from 36 million Medicare recipients, are ...
... The Minnesota Medical Association Board of Trustees decided Saturday ... Assistance Medical Care (GAMC) program, but not if such efforts include ... not cover the cost of providing care. , The Board also ... programs. The MMA sent a letter to lawmakers this week. , ...
... New collaboration leverages Joslin,s deep clinical and research expertise and ... BOSTON , Jan. 29 Joslin.org ... Center, the world,s preeminent diabetes research and clinical care organization, and ... with diabetes, today announced a new online partnership. dLife will ...
... quite some time, the "Holy Grail" in medical imaging has ... death as a means to intervene early in diseases and ... researchers at the University of Notre Dame and the Washington ... synthetic probe to target dead and dying cells in mammary ...
... Both ... symptoms of autism with a Biomedical alternative. , ... (PRWEB) January 29, 2010 -- Autism-supplements.com, a Lyndhurst New ... Jenny McCarthy and Jim Carrey’s autism organization, to help raise money and public awareness ...
Cached Medicine News:Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 2Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 3Health News:Parkinson's More Common in Northeast, Midwest 2Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 3Health News:New paper describes important advance in imaging of cell death 2Health News:Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... Sleep Hand-Held Pulse Oximeter with built-in ... sleep screening studies in the sleep ... With its easy-to-use, 2-key operation, it ... of SpO 2 , pulse rate ...
Medicine Products: